Eton Pharmaceuticals announces co-promotion agreement with Tolmar Pharmaceuticals for Alkindi Sprinkle.

Eton will leverage Tolmar’s 62-person sales force and their existing relationships in the pediatric endocrinology specialty.

Tolmar currently promotes Fensolvi (leuprolide acetate) for injectable suspension, indicated for pediatric patients 2 years of age and older with Central Precocious Puberty (CPP).

“It’s clear that physicians see the need for Alkindi Sprinkle’s accurate dosing when treating adrenal insufficiency, however, we have found that changing the decades old prescribing habits of pediatric endocrinologists is often requiring multiple face-to-face interactions. With this partnership, our reach will be increasing more than 10-fold and we will drastically increase the number of face-to-face interactions. We believe this will translate to significantly faster adoption of Alkindi Sprinkle and accelerate the time to reach peak conversion,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “We are confident Tolmar is the right partner for Alkindi Sprinkle. Their Fensolvi launch results speak for themselves and highlight their team’s ability to drive treatment change in pediatric endocrinology,” added Brynjelsen.

Tolmar’s pediatric endocrinology sales force currently promotes the specialty drug Fensolvi for CPP, a rare disease that impacts roughly one in 5,000-10,000 children in the United States. Fensolvi was launched in May 2020 and has already reached more than 1,500 patients. Under terms of the agreement, Tolmar’s sales force will promote Alkindi Sprinkle to their pediatric endocrinology targets alongside Fensolvi. Tolmar will receive a royalty on net sales growth above Alkindi Sprinkle's current baseline sales. Eton’s sales force will continue to promote the product and Eton will maintain responsibility for all non-sales force related commercial activities.